key: cord-0825399-qbkmekip
authors: Zhang, Leili; Huynh, Tien; Luan, Binquan
title: in silico Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617
date: 2021-05-14
journal: bioRxiv
DOI: 10.1101/2021.05.12.443826
sha: 1dd6e6e33027b92d90af0911c01f92a8295712aa
doc_id: 825399
cord_uid: qbkmekip

The highly infectious SARS-CoV-2 variant B.1.617 with double mutations E484Q and L452R in the receptor binding domain (RBD) of SARS-CoV-2’s spike protein is worrisome. Demonstrated in crystal structures, the residues 452 and 484 in RBD are not in direct contact with interfacial residues in the angiotensin converting enzyme 2 (ACE2). This suggests that albeit there are some possibly nonlocal effects, the E484Q and L452R mutations might not significantly affect RBD’s binding with ACE2, which is an important step for viral entry into host cells. Thus, without the known molecular mechanism, these two successful mutations (from the point of view of SARS-CoV-2) can be hypothesized to evade human antibodies. Using in silico all-atom molecular dynamics (MD) simulation as well as deep learning (DL) approaches, here we show that these two mutations significantly reduce the binding affinity between RBD and the antibody LY-CoV555 (also named as Bamlanivimab) that was proven to be efficacious for neutralizing the wide-type SARS-CoV-2. With the revealed molecular mechanism on how L452R and E484K evade LY-CoV555, we expect that more specific therapeutic antibodies can be accordingly designed and/or a precision mixing of antibodies can be achieved in a cocktail treatment for patients infected with the variant B.1.617.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the ongoing COVID-19 pandemic has evolved into several new dominant variants with major genomic changes through mutations. Mutations in viruses arise (partly) as a result of low polymerase fidelity of viral replication but become a survival mechanism for viruses to adapt to new hosts and environments. 1 Although the majority of viral mutations are benign with most of them weeded out immediately, the current pandemic provides a suitable environment for SARS-CoV-2 to make natural selection of rare-acted but favorable mutations to strengthen its survival capability. Since the virus surface spike protein plays an important role in mediating SARS-CoV-2 entry into human cells and is the target for vaccine and therapeutic development, any mutations on this region may have biological significance as it could affect the viral infectivity and antigenicity. [2] [3] [4] Indeed, experimental studies showed that the D614G mutation discovered at the earlier stage of the pandemic enhances the virus fitness and increases its transmission. 5, 6 Similarly, the N501Y mutation found in the B.1.1.7, B.1.351 and B.1.1.28.1 variants has been demonstrated to increase the binding affinity between the receptor-binding domain (RBD) and its human receptor ACE2 (hACE2), making these variants more transmissible. [7] [8] [9] Moreover, experimental and computational studies have showed that the K417N and E484K found in the B.1.351 variant could evade neutralization by many monoclonal antibodies. 10, 11 Recently, a variant named B.1.617 that carries two mutations including the L452R and E484Q has been designated as variant of interest (VOI) by the World Health Organization (WHO), suggesting that B.1.617 potentially could have higher transmissibility, severity or reinfection risk and is required continuous monitoring. In fact, the two mutations found in B.1.617 are not completely new and have been seen in other variants separately. For example, the L452R mutation has been spotted in the B.1.427/B.1.429 variant which is known to be more contagious and is capable of escaping antibody neutralization. 12 Also, the E484Q mutation is similar to the E484K found in the B.1.351 and B.1.1.28.1. The latter were found to reduce neutralization by convalescent antisera and binding of some monoclonal antibodies and increases the binding affinity to the hACE2. 10, 11 For the B.1.617 variant, this is the first time that these two mutations are found to coexist together, therefore it is important to understand how this variant could evade human antibodies or existing antibody drugs for treating COVID-19.

Complementary to ongoing experimental efforts, the all-atom molecular dynamics (MD) simulations with well-calibrated force fields have been widely used to explore the molecular mechanism of proteins. [13] [14] [15] [16] In this work, we carried out an in silico exploration on how a monoclonal antibody that can neutralize the wide-type SARS-CoV-2 but failed to target the B.1.617 variant. Here, we focus on the biologics drug LY-CoV555 that is a monoclonal antibody isolated from a convalescent COVID-19 patient. LY-CoV555 recognizes an epitope site in the RBD overlapping the binding site of ACE2, and was found to be efficacious on the wide-type SARS-CoV-2. 17 By combining all-atom molecular dynamics, alchemical calculations and deep learning (DL) analysis, we aim to unveil the molecular mechanism on how these two mutations in the variant B.1.617 can be evasive to LY-CoV555. Our results provide invaluable insights for future designs of more efficacious mAbs to treat COVID-19 patients infected with the variant B.1.617, and highlight the need for precision medicine (biologics) for each SARS-CoV-2 variant. To evaluate whether LY-CoV555 is still effective for the variant B.1.617 carrying the L452R and E484Q mutations, we further investigate interfacial coordinations around L452 and E484. Remarkably, both L452 and E484 play an important role in stabilizing the interfacial binding, as shown in Figure 2 . Figure From the analysis of simulation trajectory, we found that the interaction energy between L452 and I54/L55 is dominated by the van der Waals interactions, which is understandable because of the hydrophobic nature. Figure 2c shows that during the simulation this interaction reduce the potential energy by 1.2 kcal/mol averagely. In addition, two energy levels can be discerned in the time-dependent interactions (Figure 2c ), resulting from the fact that I54

can temporarily move away from L452 from time to time due to thermal fluctuations. When both I54 and L55 interacted with L452, the mean interaction energy is about -2 kcal/mol. However, with only L55 bound with L452, the interaction was weaker and the mean energy is only about -0.5 kcal/mol ( Figure 2c ).

To demonstrate that two salt-bridges shown in Figure 2b were stable, we calculated timedependent characteristic distance D, defined as the distance between the CZ atom in R50 (or R96) and the CD atom in E484 (see the inset in Figure 2d ). Figure 2d shows that the time-dependent distances D between R50 and E484 is nearly constant and the average distance is 4.1 Å. The salt-bridge between R96 and E484 has a different pose (Figure 2b ), leading to a larger average distance of 4.5 Å. Noticeably, the fluctuation in time-dependent distances is larger for the salt-bridge between R96 and E484 than for salt-bridge between R50 and E484, suggesting that the former salt-bridge is relatively weaker. Overall, the local c) Time-dependent interaction energies between L452 in RBD and I54/L55 in the V H domain of (LY-CoV555). d) Time-dependent distances between the CZ atom in (R50 or R96) and the CD atom in E484. The inset illustrates the definition of the distance D. Results for the salt-bridges R50-E484 and R96-E484 are colored in blue and orange, respectively. structure formed by E484, R50 and R96 was stable (Movie S1 in Supporting Information, because these two salt-bridges were actually buried inside the protein complex ( Figure S1 in Supporting Information). Note that generally a water-exposed salt-bridge can form and break frequently and thus their distances can have two different mean values corresponding to formed and broken states of the salt-bridge. 9 Free energy perturbation calculations for L452R and E484Q mutations Unfortunately, the importance of L452 and E484 in stabilizing the LY-CoV555's binding with RBD as shown above also indicates that L452R and E484Q mutations can be highly evasive ones for LY-CoV555. Here, we performed free energy perturbation (FEP) calculations 21 to obtain the binding free energy change (∆∆G) induced by the L452R and E484Q mutations.

As required in FEP calculations, we performed 108-ns-long MD simulations of RBD in a 0.15 M KCl electrolyte (a free state), as shown in Figure S2a in Supporting Information.

Interestingly, the saturated RMSD values for RBD's backbone atoms are around 2 Å ( Figure   S2b in Supporting Information) that is larger than the one (1.5 Å) for the complex, which is due to the flexible coil (containing E484) in the free state (Movie S2 in Supporting Information). While in the bound state, the same coil is docked at the LY-CoV555's interface (see Figure 2b ) and thus less flexible. It is worth noting that due to the flexibility of the above mentioned coil, in the variant B.1.351 the mutated K484 residue can move toward E75 in ACE2 and form a salt-bridge, 9 enhancing the binding affinity. With protein structures for both bound and free states in respective MD simulations, we applied the FEP alchemy method to obtain the binding free energy difference for L452R and E484Q mutations on the RBD. The protocol is briefly described in the Methods section and the detailed one can be found in previous works. 9

During a typical FEP calculation, the original and new residues gradually disappears and appears respectively. After the L452R mutation, Figure 3a shows R452 is in contact with those key residues that form favorable binding with the antibody CB6. 18 Thus, mutations of those residues could significantly reduce the binding affinity between RBD and an antibody.

In this work, we employed an efficient DL method (see below) to identify all residues in RBD that are important for the binding with LY-CoV555.

Residue i dynamism tensor A: CASTELO workflow. We collect data from MD simulations. On one route, we calculate the clusters of the interfacial residues with RMSD clustering. On another route, we calculate the clusters of each residue i following these steps: (1) extracting contact matrix and difference matrix from the simulations; (2) assembling dynamism tensor for residue i;

(3) compressing dimensions of the dynamism tensors with CVAE onto the latent space; (4) performing HDBSCAN clustering on the latent space for residue i. Finally, RMSD clustering results and AI-enhanced clustering results are compared with comparison metrics such as dv score. CASTELO score is calculated from the dv scores (using the equation in Methods). B: CASTELO scores are plotted for interfacial residues in RBD. The interfacial residues of RBD are defined as the residues in RBD that are within 5 Å of LY-CoV555 in its stable binding structure. Negative scores mean that the residues are beneficial. Positive scores mean that the residues are malicious.

In previous works, 23, 24 we demonstrated that our designed MD-ML workflow CASTELO was able to identify atoms or atom groups (including amino acid residues) that contributed positively and negatively to the two-body interactions (such as drug-protein interactions 23 and peptide-protein interactions 24 ), agreeing with both experimental measurements and computationally expensive free energy calculations. Here, we applied the same workflow to the MD simulation for the complex of RBD and LY-CoV555. With the simulation trajectory, we first used RMSD clustering method to determine whether the simulation contained a stable binding structure between RBD and LY-CoV555. As shown in Figure 4A , with RMSD clustering method we identified that the largest cluster of the trajectory lasted ∼169 ns far longer than the threshold of structural stability used previously (50 ns), 23, 24 which suggests that the simulation used in this study contains a stable binding structure of RBD and LY-CoV555. It is worth mentioning that this is an important first step. As we showed previously, the identification of beneficial or malicious residues relies on the comparison between the clustering results of the overall structures and the clustering of the individual residues. If the overall structures (the interfacial residues in this case) are stable, low similarity between the clusters of the stable overall trajectory and the clusters of an individual residue would mean that the individual residue is unstable. Residues such as these would be identified as ones that harm the interactions (which we call the malicious residues). On the contrary, high similarity between the clusters of the stable overall trajectory and the clusters of an individual residue would mean that the individual residue is stable. Residues such as these would be identified as ones that benefit the interactions (which we call the beneficial residues). However, if the overall structures are unstable, two problems would occur. First, in the simulations where no stable binding structures are verified, the confidence of finding the actual binding state is generally low. Therefore, predictions based on these simulations might be less meaningful.

Second, comparison metrics (i.e. dv scores) may not differentiate between unstable residues and stable residues when the overall structure is unstable. In summary, verifying that our simulation contains a stable binding structure of RBD-LY-CoV555 is the prerequisite of the subsequent CASTELO analysis.

We then calculated the contact matrix and dynamism tensor (see Methods) at every time frame t of the simulation (showing examples in Figure 4A ). In order to find the clusters for individual residues, we used CVAE and HDBSCAN (see Methods section) on the calculated dynamism tensor at all time frames. Then, we utilize RMSD clustering results (using the interfacial residues) calculated above and CVAE clustering results calculated with dynamism tensors of the individual residues to evaluate the CASTELO scores for each of the interfacial residues (see Methods). The scores are plotted in Figure 4B , showing that L492, N450, L452

and E484 in RBD are among the four most beneficial residues to the complex of RBD and LY-CoV555 interactions. Intriguingly, from our MD simulation trajectory we found that L492 and L452 in RBD share close contacts with L55 of V H chain, which indicates an important hydrophobic core at the complex interface. Thus, similar to the L452R mutation, the possible L492R mutation can also reduce the LY-CoV555's binding with RBD. N450 of RBD is physically close to this hydrophobic core, while sharing hydrogen bond through a water chain with S30 of V H . Thus, the mutation N450I (occurred with a single nucleotide variation in their codon codes ) can disrupt this interfacial hydrophilic interaction and weaken the LY-CoV555's binding with RBD. E484 of RBD, on the other hand, seems to stabilize the binding with a completely different mechanism by forming salt-bridges with R50 of V H and R96 of V L , as pointed out before. In addition, it is worth highlighting that CASTELO identified four other beneficial residues S494, Q493, F490 and V483 (Figure 4b ) whose mutations were proven to be evasive for LY-CoV555 in experiment. 22 In contrast, R346, F486, N487 and I472 are among the four most malicious residues to the interactions between RBD and LY-CoV555. R346 of RBD was picked out, because it was highly flexible when being completely solvated in the electrolyte. Normally one should ignore a pick like this because it facilitates the solvation of the protein, even though this residue might be categorized as an interfacial residue by conventional standards. F486 of RBD forms an imperfect π − π stacking with slightly hydrophilic Y92 of V H in LY-CoV555, while being close to hydrophilic N487. As a result, N487 of RBD becomes unfavorable as well and was identified by CASTELO as a malicious residue. Finally, the hydrophobic I472

of RBD interestingly contacted with the highly hydrophilic E484-R50 and E484-R96 salt bridges. As a result, it was picked as an unstable residue by CASTELO. Therefore, any mutation among these four might increase the binding affinity between LY-CoV555 and RBD, which can be catastrophic for the viral survival in a host.

In this in silico study, we assumed that LY-CoV555 targets RBD-v at the same epitope, which leads to our conclusion that based on FEP calculations the double mutations L452R

and E484Q can significantly reduce LY-CoV555's binding affinity to RBD-v. Through MD simulation, we highlighted the molecular mechanism on how LY-CoV555 can be efficaciously bound with wide-type RBD but fails to bind RBD-v in variant B.1.617. Our alchemy FEP calculations show that binding free energy changes for L452R and E484K mutations are 3.04 and 22.22 kcal/mol respectively, indicating that these two mutations substantially weaken the binding between RBD-v and LY-CoV555 and thus are evasive. However, we emphasize that these two mutations are not resistant to LY-CoV016 (or Etesevimab that is another antibody in Lilly's antibody cocktail), as shown in Figure S3 in the Supporting Information.

We We used the CHARMM36m force field 29 for proteins, the TIP3P model 30, 31 for water, the standard force field 32 for K + and Cl − . The periodic boundary conditions (PBC) were applied in all three dimensions. Long-range Coulomb interactions were calculated using particlemesh Ewald (PME) full electrostatics with the grid size of about 1 Å in each dimension.

The pair-wise van der Waals (vdW) energies were computed using a smooth (10-12 Å) cutoff. The temperature T was kept at 300 K by applying the Langevin thermostat, 33 while the pressure was maintained constant at 1 bar using the Nosé-Hoover method. 34 

CASTELO, 23 or "clustered atom subtypes aided lead optimization", is a combined molecular dynamics (MD) and machine learning (ML) method that identifies improvable atoms or atom groups in a drug lead molecule (such as small molecule drugs 23 and peptides 24 ). We followed the previous study, 24 where CASTELO was applied to a protein-peptide binding simulations and applied the same workflow on the RBD-antibody binding simulations. In short, we calculated the contact matrix between RBD and antibody at each individual timeframe (time t) of the simulations. The elements of the calculated contact matrix consisted of the closest-heavy distances between M residues of antibody and N residues of the RBD.

Note that closest-heavy distance between residue i and residue j is calculated as the minimal distance between all interfacial pairs of heavy atoms (non-hydrogen atoms) in these two residues. In addition to the contact matrix, we enriched the extracted information at time t with the difference contact matrix between t and t − δ. The resulting 2 × M × N matrix is coined "dynamism tensor", which contains both static contact information and dynamic information of the protein binding complex at time t. Subsequently, we used Convolutional

Variational Autoencoders (CVAE) to represent each dynamism tensor in a d-dimensional latent space (with a vector of d elements). For each residue, we used HDBSCAN 39 as our clustering method to identify the clusters at the latent space ( Figure 4A ). As a comparison, we used conventional RMSD clustering method (quality threshold method in VMD 40 ) to identify the clusters of the binding interface (defined as the residues within 5 Å of its binding partner). Eventually, we compared the individual residue-wise clusters and the binding interface clusters with comparison metrics (summarized as the CASTELO score, plotted in Figure 4B ) to rank the residues from most beneficial to the protein-protein interactions to the most malicious to the interactions. To calculate the CASTELO scores, we first utilize the dv scores presented by Gionis et al. 41 that compares two clustering results (see Bell et al. 24 ). We then normalize the dv scores using the equation: (dv i − Σ i dv/N )/max i (dv i − Σ i dv/N ), which is denoted as the CASTELO score. All parameters were adopted from a previous study, 24 except that the cutoff distance of the contact matrix was changed to 4 Å and convolutional filter size was changed to 1 × 3 to accommodate the small cutoff distance. 

Mechanisms of viral mutation

Structural basis of receptor recognition by SARS-CoV-2

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

Spike mutation D614G alters SARS-CoV-2 fitness

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations

Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7

Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 2021, 13. Karplus, M.; McCammon, J. Molecular dynamics simulations of biomolecules

Challenges in protein-folding simulations

in silico Exploration of Molecular Mechanism of Clinically Oriented Drugs for Inhibiting SARS-CoV-2's Main Protease

Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates

Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Solvent-Accessible Surfaces of Proteins and Nucleic Acids

Free energy calculations

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

CASTELO: Clustered Atom Subtypes aidEd Lead Optimization-a combined machine learning and molecular modeling method

Dynamics-based peptide-MHC binding optimization by a convolutional variational autoencoder: a usecase model for CASTELO

Potent neutralizing antibodies against SARS-CoV-2 identified by highthroughput single-cell sequencing of convalescent patients' B cells

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Scalable Molecular Dynamics with NAMD

CHARMM36m: an improved force field for folded and intrinsically disordered proteins

Comparison of Simple Potential Functions for Simulating Liquid Water

Simulation of Activation Free Energies in Molecular Systems

Finite representation of an infinite bulk system: Solvent boundary potential for computer simulations

Computer Simulation of Liquids

An Analytical Version of the SHAKE and RATTLE Algorithm for Rigid Water Molecules

Reversible multiple time scale molecular dynamics

Free Energy of Ionic Hydration

Mechanism of Divalent-Ion-Induced Charge Inversion of Bacterial Membranes

Density-based clustering based on hierarchical density estimates

VMD: visual molecular dynamics